Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This study evaluated the efficacy and safety of tofacitinib for treating severe alopecia areata in five patients, finding that three responded favorably with mild side effects, supporting its potential use based on existing research.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

This article discusses the history and understanding of Tay syndrome, recognizing it as a distinct condition related to ichthyotic erythroderma, mental retardation, and brittle hair but reports no new clinical results.

This study found that tideglusib delivered topically in a bacterial cellulose hydrogel showed positive effects on the wound healing of rat palatal mucosa, as observed through macroscopic, histomorphometric, and immunohistochemical evaluations.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

This case report highlights a rare association between congenital triangular alopecia and vitiligo, noting that treatment with tofacitinib improved the patient's vitiligo but not the alopecia.

This study describes a clinical investigation of telogen effluvium with iron deficiency anemia, comparing treatment with Fe2+ salts alone to Fe2+ salts plus topical Qilib, but reports no new results.

In this report, trichoscopy was highlighted as a valuable tool for diagnosing temporal triangular alopecia in children due to its ability to reveal distinctive patterns that differentiate it from similar conditions like alopecia areata, eliminating the need for invasive biopsy.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

This article discusses temporal triangular alopecia, emphasizing the need for increased awareness to prevent misdiagnosis and ineffective treatment, but reports no new clinical results.

This study found that two eco-friendly analytical methods for quantifying Finasteride and Tadalafil in a new dosage form were effective, green, and suitable for quality control.

This study found that Sithong-bao seed coat extract, with high phenolic content, exhibited the strongest antioxidant properties among certain Thai tamarind cultivars, suggesting potential for nutraceutical development.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This paper highlights a case where a 2-year-old boy with temporal triangular alopecia was initially misdiagnosed with alopecia areata, emphasizing the importance of dermoscopy for accurate early diagnosis to avoid unnecessary treatments.

This study found that 2-hydroxy-1,4-naphthoquinone was the most effective inhibitor of steroid 5α-reductase, showing stronger inhibition than avicequinone C in HaCaT cell assays.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

In this clinical trial, Tofacitinib effectively promoted hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis, with 75.6% experiencing no side effects, making it a promising treatment option according to the study.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

This study developed a multifunctional hydrogel, QTMP-Gel, which significantly accelerated wound healing in an oral mucositis hamster model by providing antioxidant and antibacterial effects, reducing inflammation, and controlling infection.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This report suggests that tofacitinib may be beneficial for patients with nail disease unresponsive to other treatments.

The researchers reported that dPGS-PCL as a carrier improved the penetration of tofacitinib in an ex-vivo human skin model compared to free tofacitinib, but did not show significant differences in inhibiting IL-6 and IL-8 during short incubation.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This study found that enhancing quercetin bioavailability with EubioQuercetin significantly improved external aging signs in mice and influenced gut microbiota and intestinal gene expression, suggesting potential modulation through the gut microbiota–intestinal barrier axis.

This study developed a sensor that effectively measures Tl+ cation in solutions with a wide dynamic range and low detection limit, responding linearly within the concentration range 1.0 × 10−8 to 1.0 × 10−1M.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.